Median (Interquartile range) | 41.5 (34-50) |
Female | 126 (98.4) |
Male | 2 (1.6) |
0 | 114 (89.1) |
1 | 14 (10.9) |
BRCA1 | 79 (61.7) |
BRCA2 | 49 (38.3) |
0-2 cm –T1 | 79 (79.0) |
2-5 cm- T2 | 15 (15.0) |
5 cm and above-T3 | 4 (4.0) |
61 (47.7) | |
Stage I | 30 (23.4) |
Stage II | 53 (41.4) |
Stage III | 29 (22.7) |
Stage IV | 14 (10.9) |
ER, %, median (IQR) | 45 (0-90) |
PgR, %, median (IQR) | 0 (0-65) |
1+ | 17 (13.3) |
2+ | 22 (17.2) |
3+ | 8 (6.3) |
cerbB2, FISH | 12 (9.4) |
Ki-67, %, median (IQR) | 30 (15-50) |
Triple negative | 56 (43.8) |
Luminal Her2- | 57 (44.5) |
Luminal Her2+ | 9 (7.0) |
cerbB2+ | 3 (2.3) |
Right | 65 (50.8) |
Left | 58 (45.3) |
Bilateral | 5 (3.9) |
14 (10.9) | |
Lung | 10 (7.8) |
Bone | 18 (14.1) |
Liver | 8 (6.3) |
Lymph node | 4 (3.1) |
64 (50.0) | |
Parent diagnosis (n=15) | 51 (46-57.5) |
Sibling diagnosis (n=7) | 44 (35-49) |
Median (Interquartile range) | 50 (44-59) |
0 | 43 (68.3) |
1 | 20 (31.7) |
Ovary | 58 (92.1) |
Endometrium | 2 (3.2) |
Peritoneum | 1 (1.6) |
Stage I | 12 (19.0) |
Stage II | 9 (14.3) |
Stage III | 26 (41.3) |
Stage IV | 12 (19.0) |
20 (31.7) | |
Serous | 48 (76.2) |
Endometrioid | 9 (14.3) |
Serous+Endometrioid | 4 (6.3) |
13 (20.6) | |
Median (Interquartile range) | 155 (41-560) |
BRCA1 | 49 (77.8) |
BRCA2 | 14 (22.2) |
Median (Interquartile range) | 6 (6-6) |
CR | 43 (68.3) |
PR | 12 (19.2) |
<6 months | 0 |
6-12 months | 14 (22.2) |
>12 months | 28 (44.4) |
Median (minimum-maximum) | 1 (1-6) |
24 (38.1) | |
Parent diagnosis | 63 (58-68) |
Median (Interquartile range) | 57 (57-60) |
3 (42.9) | |
47 (14-74) | |
7 (100) | |
28 (14-58) | |
Docetaxel at 1 line | 7 (100) |
Enzalutamid at 2 line | 5 (71.4) |
Abiraterone at 2 line | 1 (14.2) |
Lutesyum at 3 line | 3 (42.9) |
Olaparib at 3 line | 5 (71.4) |
13 (12-14) | |
Enzalutamide | 5 (71.4) |
Abiraterone | 1 (14.2) |
Cabazitaxel | 1 (14.2) |
Median (Interquartile range) | 45 (38-54) |
Female | 190 (95.0) |
Male | 10 (5.0) |
0 | 162 (81.0) |
1 | 38 (19.0) |
Breast | 128 (64.0) |
Genital | 63 (31.5) |
Prostate | 7 (3.5) |
Pancreas | 2 (1.0) |
91 (45.5) | |
First-degree | 67 (33.5) |
Second degree | 22 (11.0) |
Third degree | 2 (1.0) |
Parent diagnosis | 57 (50-66) |
Sibling diagnosis | 44.5 (35-49) |
Second relatives | 40 (35.5-48.5) |
12 (6.0) | |
Synchronous | 1 (0.5) |
Metachronous | 11 (5.5) |
Breast-ovary | 11 (5.5) |
BRCA-1 | 130 (65.0) |
BRCA-2 | 70 (35.0) |